Notably, dacomitinib has been found to be effective against chemotherapy‐resistant HER2/neu gene‐amplified uterine serous carcinoma,[36] but there are no more studies on dacomitinib and endometrial cancer. Here, ERBB2 is linked to endometrial serous adenocarcinoma.